Introduction
Re-sternotomy for cardiac surgery remains a challenging procedure with associated morbidity and mortality (1,2). Re-sternotomy is more challenging with patent coronary artery bypass grafts (CABG) due to risk of graft injury and myocardial jeopardy. With increasing life expectancy and a wider use of biological prostheses, a greater number of patients would need re-sternotomy for aortic valve replacement (AVR) later in life. Transcatheter valve therapy now presents a compelling, safe option to avoid re-sternotomy especially in high to intermediate risk severe aortic stenosis patients with patent coronary grafts not needing any other concomitant procedures (3,4). The aim of this study was to evaluate early and long-term outcomes of patients who underwent AVR with a re-sternotomy with patent CABG.